Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Equivalents (2016 - 2025)

UroGen Pharma's Cash & Equivalents history spans 10 years, with the latest figure at $110.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 35.61% year-over-year to $110.7 million; the TTM value through Dec 2025 reached $110.7 million, down 35.61%, while the annual FY2025 figure was $110.7 million, 35.61% down from the prior year.
  • Cash & Equivalents reached $110.7 million in Q4 2025 per URGN's latest filing, up from $90.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $220.0 million in Q2 2024 to a low of $20.1 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $90.0 million, with a median of $92.9 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: plummeted 65.33% in 2023, then skyrocketed 992.92% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $44.4 million in 2021, then grew by 24.91% to $55.4 million in 2022, then soared by 71.46% to $95.0 million in 2023, then soared by 81.04% to $172.0 million in 2024, then crashed by 35.61% to $110.7 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Cash & Equivalents are $110.7 million (Q4 2025), $90.0 million (Q3 2025), and $92.9 million (Q2 2025).